Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fractyl Health Announces New Results From Its Rejuva® Platform
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Fractyl Health raises $110 mln in US IPO
Fractyl Health targets up to $762 mln valuation in US IPO
Fractyl Health valued at $654.6 mln in tepid debut